التفاصيل البيبلوغرافية
| العنوان: |
复发难治性多发性骨髓瘤患者应用含达雷妥尤单抗方案的效果观察 及疾病缓解影响因素分析. (Chinese) |
| العنوان البديل: |
Effect Observation and Analysis of Factors Affecting Disease Remission of Patients with Relapsed and Refractory Multiple Myeloma Treated with Daretozumab. (English) |
| المؤلفون: |
古再丽努尔, 吾甫尔, 赵佳琳, 朗涛, 黄琴, 毛敏 |
| المصدر: |
Progress in Modern Biomedicine; 2023, Vol. 23 Issue 14, p2704-2708, 5p |
| مصطلحات موضوعية: |
EXTRAMEDULLARY diseases, LOGISTIC regression analysis, LACTATE dehydrogenase, DISEASE remission, MULTIPLE myeloma, CANCER fatigue |
| مصطلحات جغرافية: |
XINJIANG Uygur Zizhiqu (China) |
| الملخص (بالإنجليزية): |
Objective: To explore the clinical efficacy and safety of daretozumab regimen in the treatment of relapsed refractory multiple myeloma(RRMM), and analyze the related factors affecting the remission of the disease. Methods: The clinical data of 50RRMM patients treated with daretozumab in the Hematology Department of the People’s Hospital of Xinjiang Uygur Autonomous Region from January 2019 to September 2022 were analyzed retrospectively. Results: After treatment, the levels of hemoglobin(Hb), lactate dehydrogenase(LDH), β2 microglobulin(β2-mg) and serum creatinine(Scr) were improved compared with those before treatment(P＜0.05). The overall clinical response rate(ORR) was 70.9 %, and the progression-free survival(PFS) was 11 months. There were statistical significance in age, recurrence times and proportion of osteolytic lesions between the two groups(P＜0.05), but there were no statistical significance in gender, immune classification, HRCA, anemia, kidney damage and proportion of extramedullary lesions between the two groups(P＞0.05). There were statistically significant differences in age, recurrence times and proportion of osteolytic lesions between the remission group and the non-remission group(P＜0.05), but no statistically significant differences in gender, immune classification, HRCA, anemia, kidney damage and proportion of extramedullary lesions between the two groups(P＞0.05). Multivariate Logistic regression analysis showed that the number of recurrence was a risk factor for the response rate of darettuzumab regimen(P=0.019, OR=1.956). Conclusion: The regimen containing daretozumab in the treatment of RRMM has good efficacy and safety, and its efficacy can be affected by the number of recurrences. [ABSTRACT FROM AUTHOR] |
| Abstract (Chinese): |
探讨达雷妥尤单抗方案治疗复发难治性多发性骨髓瘤（RRMM)的临床疗效及安全性，并分析影响疾病缓解的相关因 素。方法：回顾性分析 2019 年 1 月 ~2022 年 9 月新疆维吾尔自治区人民医院血液科收治的接受达雷妥尤单抗治疗的 50 例 RRMM 患者临床资料。结果：治疗后患者血红蛋白（Hb), 乳酸脱氢酶（LDH), 茁2 微球蛋白（茁2-MG), 血肌酐（Scr)水平均较治疗前 明显改善义（P＜0.05)。临床总有效率（ORR)为 70.9%，无进展生存期（PFS)为 11 月。两组在年龄, 复发次数, 溶骨性病变比例上比 较有统计学意义（P＜0.05)，而在性别, 免疫分型, HRCA, 贫血, 肾损害, 髓外病变比例上比较无统计学意义（P＞0.05)。疾病缓解组 与未缓解组在年龄, 复发次数, 溶骨性病变比例上比较有统计学意义（P＜0.05)，而在性别, 免疫分型, HRCA, 贫血, 肾损害, 髓外 病变比例上比较无统计学意义（P＞0.05)。多因素 Logistic 回归分析显示，复发次数是影响达雷妥尤单抗方案治疗缓解率的危险 因素（P=0.019，OR=1.956)。结论：含达雷妥尤单抗方案治疗 RRMM 具有较好的疗效及安全性，其疗效可受到复发次数的影响。 [ABSTRACT FROM AUTHOR] |
|
Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
